Revvity, Inc. · NYSE (us_market)
Healthcare · Diagnostics & Research · United States
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-22$117.75 RISE2026-04-29$82.26 PEAK2026-05-29$104.55 127d | -30.1% 97d | Missed | Missed | — | — | +27.1% 30d | Missed |
DROP2026-01-22$117.75 RISE2026-03-27$83.90 PEAK2026-05-29$104.55 127d | -28.7% 64d | Missed | Missed | — | — | +24.6% 63d | Missed |
DROP2025-07-25$103.67 RISE2025-09-10$82.50 PEAK2025-11-25$105.57 123d | -20.4% 47d | Missed | Missed | — | — | +28.0% 76d | Missed |
DROP2025-01-30$126.84 RISE2025-06-02$89.32 PEAK2025-07-25$103.67 176d | -29.6% 123d | Missed | Missed | — | — | +16.1% 53d | Missed |
DROP2023-07-21$130.87 RISE2023-10-30$82.08 PEAK2024-01-10$111.68 173d | -37.3% 101d | Missed | Missed | — | — | +36.1% 72d | Missed |
DROP2023-02-02$144.38 RISE2023-06-09$111.09 PEAK2023-07-21$130.87 169d | -23.1% 127d | Missed | Missed | — | — | +17.8% 42d | Missed |
DROP2022-08-11$160.96 RISE2022-10-12$117.01 PEAK2022-12-13$147.94 124d | -27.3% 62d | Missed | Missed | — | — | +26.4% 62d | Missed |
DROP2022-03-22$184.54 RISE2022-07-18$132.37 PEAK2022-08-11$160.96 142d | -28.3% 118d | Missed | Missed | — | — | +21.6% 24d | Missed |
DROP2021-12-31$201.06 RISE2022-01-27$163.85 PEAK2022-02-09$189.26 40d | -18.5% 27d | Missed | Missed | — | — | +15.5% 13d | Missed |
DROP2021-01-07$160.53 RISE2021-05-04$127.81 PEAK2021-07-29$179.30 203d | -20.4% 117d | Missed | Missed | — | — | +40.3% 86d | Missed |
DROP2021-01-07$160.53 RISE2021-03-10$120.35 PEAK2021-05-20$147.68 133d | -25.0% 62d | Missed | Missed | — | — | +22.7% 71d | Missed |
DROP2020-01-15$101.73 RISE2020-03-16$66.71 PEAK2020-06-08$105.31 145d | -34.4% 61d | Missed | Missed | — | — | +57.9% 84d | Missed |
Revvity has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Revvity has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Revvity, Inc.'s ( NYSE:RVTY ) stock was strong despite it releasing a soft earnings report last week. We think that...
Revvity, Inc.'s ( NYSE:RVTY ) stock was strong despite it releasing a soft earnings report last week. We think that...
Revvity’s first quarter results were well received by the market, as the company delivered stronger-than-expected organic growth and margins. Management attributed the positive performance to solid execution in both the Life Sciences and Diagnostics segments, with particular momentum in reagents, instruments, and reproductive health. CEO Prahlad Singh highlighted that “the better-than-anticipated revenue and margin performance” reflected resilience across key customer groups, including pharma, b
Revvity’s first quarter results were well received by the market, as the company delivered stronger-than-expected organic growth and margins. Management attributed the positive performance to solid execution in both the Life Sciences and Diagnostics segments, with particular momentum in reagents, instruments, and reproductive health. CEO Prahlad Singh highlighted that “the better-than-anticipated revenue and margin performance” reflected resilience across key customer groups, including pharma, b
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
Revvity, Inc. (RVTY) Bank of America Global Healthcare Conference 2026 May 13, 2026 12:20 PM EDTCompany ParticipantsStephen Willoughby - Senior VP of...
Presenter SpeechMichael Ryskin [Audio Gap] diagnostics team. And for our next session, we're joined by Revvity. Pleased to be joined by Steve Willoughby, Senior VP, Investor Relations, ESG and
WALTHAM, Mass., May 13, 2026--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company’s FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single platfor
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Revvity, Inc. reported past first‑quarter 2026 results with sales of US$711.12 million, modestly lower net income of US$40.72 million, and slightly higher diluted earnings per share, while also affirming a quarterly dividend of US$0.07 per share payable in August 2026. Alongside the earnings, Revvity outlined plans to divest its China Immunodiagnostics business, updated its 2026 revenue and adjusted EPS guidance, and adopted a bylaw change allowing 25% shareholders to call special meetings,...
Revvity, Inc. reported past first‑quarter 2026 results with sales of US$711.12 million, modestly lower net income of US$40.72 million, and slightly higher diluted earnings per share, while also affirming a quarterly dividend of US$0.07 per share payable in August 2026. Alongside the earnings, Revvity outlined plans to divest its China Immunodiagnostics business, updated its 2026 revenue and adjusted EPS guidance, and adopted a bylaw change allowing 25% shareholders to call special meetings,...
Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the price target from $95 to $105.
JP Morgan analyst Casey Woodring maintains Revvity (NYSE:RVTY) with a Neutral and lowers the price target from $96 to $90.
TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $115 to $120.
Stifel analyst Daniel Arias maintains Revvity (NYSE:RVTY) with a Hold and lowers the price target from $110 to $100.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| RVTY | +20.62% | +9.37% | +8.06% | +15.63% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +17.65% | +15.09% | +11.51% | +2.94% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 4.31M | $377.63M | 0.01% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 349.4K | $30.61M | 0.00% | Added+159.1% | 2026-03-31 |
| Bridgewater | macro | 37.1K | $3.25M | 0.01% | New | 2026-03-31 |
| CapResearch | fundamental | 10.5K | $917.28K | 0.00% | Added+77.3% | 2026-03-31 |
| TRowePrice | fundamental | 10.09M | $884.00K | 0.10% | Added+17.2% | 2026-03-31 |
| Wellington | fundamental | 8.0K | $705.17K | 0.00% | Trimmed-4.5% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-11 | Barrett Peter | Director | A Grant / award | 1,265 | — | +$0 |
| 2026-05-11 | Barrett Peter | Director | A Grant / award | 1,015 | — | +$0 |
| 2026-05-11 | Witz Pascale | Director | A Grant / award | 1,265 | — | +$0 |
| 2026-05-11 | Witz Pascale | Director | A Grant / award | 1,015 | — | +$0 |
| 2026-05-11 | McMurry-Heath Michelle | Director | A Grant / award | 1,265 | — | +$0 |
| 2026-05-11 | McMurry-Heath Michelle | Director | A Grant / award | 1,015 | — | +$0 |
| 2026-05-11 | Vounatsos Michel | Director | A Grant / award | 1,265 | — | +$0 |
| 2026-05-11 | Vounatsos Michel | Director | A Grant / award | 1,015 | — | +$0 |
| 2026-05-11 | Chapin Samuel R. | Director | A Grant / award | 1,265 | — | +$0 |
| 2026-05-11 | Chapin Samuel R. | Director | A Grant / award | 1,015 | — | +$0 |
| 2026-05-11 | Witney Frank | Director | A Grant / award | 1,265 | — | +$0 |
| 2026-05-11 | Witney Frank | Director | A Grant / award | 1,015 | — | +$0 |
| 2026-05-11 | Klobuchar Michael A | Director | A Grant / award | 1,265 | — | +$0 |
| 2026-05-11 | Klobuchar Michael A | Director | A Grant / award | 1,015 | — | +$0 |
| 2026-05-11 | Vandebroek Sophie V. | Director | A Grant / award | 1,265 | — | +$0 |
| 2026-05-11 | Vandebroek Sophie V. | Director | A Grant / award | 1,015 | — | +$0 |
| 2026-05-11 | MICHAS ALEXIS P | Director | A Grant / award | 1,467 | — | +$0 |
| 2026-05-11 | MICHAS ALEXIS P | Director | A Grant / award | 1,217 | — | +$0 |
| 2026-04-22 | Gonzales Anita | Vice President and CAO | S Open-market sale | 80 | $92.80 | −$7.4K |
| 2026-03-18 | Gonzales Anita | Please See Remarks | A Grant / award(deriv) | 4,576 | — | +$0 |
| 2026-03-18 | Gonzales Anita | Please See Remarks | A Grant / award | 1,600 | — | +$0 |
| 2026-03-10 | Gonzales Anita | Please See Remarks | A Grant / award(deriv) | 1,616 | — | +$0 |
| 2026-03-10 | Gonzales Anita | Please See Remarks | A Grant / award | 1,721 | — | +$0 |
| 2026-02-26 | Victor Miriame | Please See Remarks | M Option exercise(deriv) | 1,862 | — | +$0 |
| 2026-02-26 | Victor Miriame | Please See Remarks | S Open-market sale | 1,862 | $97.13 | −$180.9K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-27upcoming | 1.22 | — | — |
| 2026-05-05 | 1.01 | 1.06 | +4.47% |
| 2026-02-02 | 1.58 | 1.70 | +7.80% |
| 2025-10-27 | 1.14 | 1.18 | +3.63% |
| 2025-07-28 | 1.14 | 1.18 | +3.36% |
| 2025-04-28 | 0.95 | 1.01 | +6.39% |
| 2025-01-31 | 1.38 | 1.42 | +3.10% |
| 2024-11-04 | 1.13 | 1.28 | +13.60% |
| 2024-07-29 | 1.12 | 1.22 | +9.15% |
| 2024-04-29 | 0.94 | 0.98 | +4.72% |
| 2024-02-01 | 1.16 | 1.25 | +7.47% |
| 2023-10-30 | 1.19 | 1.18 | -1.11% |
| 2023-08-01 | 1.19 | 1.21 | +2.00% |
| 2023-05-11 | 1.02 | 1.01 | -1.27% |
| 2023-02-14 | 1.66 | 1.70 | +2.34% |
| 2022-11-08 | 1.48 | 1.51 | +2.37% |